Actuate Therapeutics, Inc. Proceeds from Issuance of Private Placement
Actuate Therapeutics, Inc. (ACTU) reported Proceeds from Issuance of Private Placement of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-08-14
- Actuate Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2025-12-31 was $0.00.
- Actuate Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2025-09-30 was -$29.08K.
- Actuate Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2024-12-31 was $0.00.
- Actuate Therapeutics, Inc. proceeds from issuance of private placement for the quarter ending 2024-09-30 was $0.00.
- Actuate Therapeutics, Inc. proceeds from issuance of private placement for fiscal 2025 was $4.59M.
- Actuate Therapeutics, Inc. proceeds from issuance of private placement for fiscal 2024 was $0.00.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$29.08K derived: sum of 2 quarters · filed 2026-03-26 | $4.59M 10-K · filed 2026-03-26 | |
| 2025-09-30 | -$29.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.59M 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $4.62M 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 10-K · filed 2026-03-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |